Short Interest in BioLineRx Ltd. (NASDAQ:BLRX) Increases By 76.1%

BioLineRx Ltd. (NASDAQ:BLRX) saw a significant increase in short interest in February. As of February 15th, there was short interest totalling 216,400 shares, an increase of 76.1% from the January 31st total of 122,900 shares. Currently, 5.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 219,300 shares, the short-interest ratio is currently 1.0 days.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BLRX. HC Wainwright reduced their target price on BioLineRx from $840.00 to $360.00 and set a “buy” rating on the stock in a report on Monday, November 25th. StockNews.com assumed coverage on BioLineRx in a research report on Tuesday, February 4th. They issued a “hold” rating for the company.

BioLineRx Price Performance

NASDAQ BLRX traded down $0.19 on Monday, hitting $3.16. 60,732 shares of the company were exchanged, compared to its average volume of 64,056. BioLineRx has a 1-year low of $3.09 and a 1-year high of $57.20. The firm has a 50 day moving average of $5.17 and a two-hundred day moving average of $14.28. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11. The company has a market cap of $10.52 million, a P/E ratio of -0.36 and a beta of 1.41.

Hedge Funds Weigh In On BioLineRx

An institutional investor recently bought a new position in BioLineRx stock. Highbridge Capital Management LLC acquired a new position in BioLineRx Ltd. (NASDAQ:BLRX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned about 50.50% of BioLineRx at the end of the most recent reporting period. 1.56% of the stock is currently owned by hedge funds and other institutional investors.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.